This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InterMune: Weak Esbriet Sales But In-Line Pricing

BRISBANE, Calif. ( TheStreet) -- InterMune (ITMN) reported weak sales of its lung disease therapy Esbriet for the second quarter but the company did manage to negotiate final pricing with German authorities that meets Wall Street expectations.

Esbriet sales for the June quarter totaled $5.5 million, all in Germany where InterMune launched the drug for idiopathic pulmonary fibrosis last September. While second-quarter sales were up 12% sequentially, analysts on average were expecting Esbriet sales of $7 million-plus.

InterMune did not disclose the number of new patients starting Esbriet therapy in the second quarter, only saying the number was up "significantly" over the first quarter. Previously, InterMune said 363 patients started Esbriet therapy in the first quarter, down from 402 new patient starts in the fourth quarter last year.

The company also said it had finalized negotiations with German authorities for a final reimbursement price of Esbriet to be approximately $33,000 per patient per year. That represents a 10% discount from the current Esbriet price but within the $30,000 range that Wall Street expected.

InterMune is still negotiating Esbriet pricing with other European countries where it expects to launch the drug later this year, including France, Italy, Belgium, Spain, the Netherlands and Finland. InterMune will launch Esbriet in the United Kingdom and Ireland in the first quarter 2013.

Esbriet sales for 2012 will be in the range of $20-25 million, below consensus of $41 million, while total operating expenses are expected to be in the range of $200-235 million, InterMune said.

Intermune reported net income of $500,000, or a penny per share in the second quarter, compared to a net loss of $39.9 million, or 68 cents per share, in the same quarter of 2011. The net income in the June quarter reflects income from discontinued operations of $51.4 million related to the sale of the drug Actimmune completed in June.

InterMune shares were down 6 cents to $11.65 in Monday pre-market trading.

A calendar of biotech earnings for the week, with consensus estimates, can be found here.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ITMN $73.89 -0.03%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs